Organization (Industry)
Spero Therapeutics, Inc.
ClinicalTrials.gov lists Spero Therapeutics, Inc. as lead sponsor of 22 trials. It has 8 active development programs and 6 approved assets.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials started per year with this organization as sponsor or collaborator, 1990 onward. The series also counts trials where the organization is a collaborator; the lead-sponsor trial count does not.
2026 is partial: 0 registered with a 2026 start date. The dashed outline is the pace from the 0 registered with a start date through September, planned starts included, not adjusted; not a forecast. No forecast is made for this organization: it averages 1.4 trial starts a year over the five years to September, under the 5 a year the method needs.
This page covers Spero Therapeutics, Inc.: 22 lead-sponsored trials and 2 legal-entity registrations.
Disease areas (5)
Shown in this order: most trials first.
| Disease area | Trials |
|---|---|
| Mycobacterium Infections, Nontuberculous | 2 |
| Mycobacterium avium-intracellulare Infection | 2 |
| Diabetes Mellitus | 1 |
| Urinary Tract Infections | 1 |
| Wound Infection | 1 |
Trials by start year as sponsor or collaborator (9)
Shown in this order: most recent first. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Show the table of trials by start year as sponsor or collaborator
| Year | Trials started |
|---|---|
| 2024 | 1 |
| 2023 | 4 |
| 2022 | 2 |
| 2021 | 3 |
| 2020 | 7 |
| 2019 | 2 |
| 2018 | 2 |
| 2017 | 2 |
| 2016 | 1 |
Recruitment duration, a model prediction: none of the 22 trials evaluated at the 2026-10-09 snapshot is predicted and still running. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
Active development programs (8)
Shown in this order: max phase, then active trials.
| Drug | Disease area | Max phase | Trials |
|---|---|---|---|
| Dummy Infusion | Urinary Tract Infections | Phase 3 | 1 |
| Imipenem + Cilastatin | Urinary Tract Infections | Phase 3 | 1 |
| TBP-PI-HBr | Urinary Tract Infections | Phase 3 | 1 |
| Dummy Tablets | Urinary Tract Infections | Phase 3 | 1 |
| SPR720 500 mg | Mycobacterium Infections, Nontuberculous | Phase 2 | 1 |
Showing 5 of 8 active programs.
Approved assets (6)
Shown in this order: max phase first.
| Drug | Trials |
|---|---|
| Ertapenem | 1 |
| Omeprazole | 1 |
| Ethambutol | 1 |
| Ceftazidime | 1 |
| Aztreonam | 1 |
Showing 5 of 6 approved assets.
Sponsor delivery record (1)
Enrollment hit target: the share of this sponsor's lead-sponsored trials whose actual enrollment reached the planned enrollment. On time: the share whose actual primary completion date was no later than the planned date. Each share counts only trials where we observed an estimated figure before the actual one, and n is that number of trials. Below 5 trials the count is shown as a fraction, not a percentage.
| Enrollment | Timeline |
|---|---|
| 43% hit target (n=14) | 43% on time (n=14) |
Journals published in (3)
Shown in this order: most published in first.
| Journal | Publications |
|---|---|
| Antimicrobial agents and chemotherapy | 7 |
| The Lancet. Microbe | 1 |
| The New England journal of medicine | 1 |
US granted patents (1)
Patents are not classified by disease area in the source, so this is the organization's overall portfolio, not a split by disease.
| US patents granted | Granted in the last 5 years | Most recent grant |
|---|---|---|
| 7 | 6 | 2025-02-18 |
SEC-reported annual financials (11)
Shown in this order: newest fiscal year first; SEC EDGAR XBRL companyfacts, USD as reported.
| Fiscal year | Revenue (USD) | Net income (USD) | R&D (USD) |
|---|---|---|---|
| 2025 | 12,586,000 | 8,572,000 | 38,467,000 |
| 2024 | 371,000 | -68,566,000 | 96,757,000 |
| 2023 | 933,000 | 22,806,000 | 51,440,000 |
| 2022 | 2,503,000 | not reported | 47,593,000 |
| 2021 | 3,070,000 | -89,800,000 | 64,526,000 |
| 2020 | 258,000 | -78,300,000 | 67,003,000 |
| 2019 | 4,742,000 | -60,900,000 | 65,775,000 |
| 2018 | 3,966,000 | -41,700,000 | 33,885,000 |
| 2017 | 1,979,000 | -38,743,000 | 32,869,000 |
| 2016 | 335,000 | -25,491,000 | 26,333,000 |
Showing 10 of 11 fiscal years.
Financing and grant events (37)
Shown in this order: most recent first.
| Date | Round type | Amount (USD) | Source |
|---|---|---|---|
| 2026-07-08 | Royalty / licensing | 106,575,000 | Sec extracted |
| 2026-07-08 | Royalty / licensing | not disclosed | Sec extracted |
| 2025-12-19 | Royalty / licensing | not disclosed | Sec extracted |
| 2024-09-30 | NIH grant | 3,424,537 | Reporter |
| 2024-05-29 | Other financing | not disclosed | Sec extracted |
Showing 5 of 37 events.
Climate targets, as filed (1)
| Reporting year | Net-zero target |
|---|---|
| 2025 | not disclosed |
Workforce and board diversity, as filed (1)
| Reporting year | Workforce % women | Board % women |
|---|---|---|
| 2025 | not disclosed | not disclosed |
Organization relationships (2)
Shown in this order: most evidence first.
| Related organization | Relationship | Evidence |
|---|---|---|
| Iqvia Holdings Inc. | Uses vendor | 1 |
| Covance (United States) | Uses vendor | 1 |
Latest dated events (72)
Shown in this order: newest first.
| Date | Event | Source |
|---|---|---|
| 2026-07-08 | Royalty / licensing | Funding rounds and grants (NIH RePORTER + SEC EDGAR) |
| 2026-07-08 | Royalty / licensing | Funding rounds and grants (NIH RePORTER + SEC EDGAR) |
| 2026-06-18 | PDUFA decision date | Regulatory decision dates extracted from SEC filings |
| 2025-12-19 | Royalty / licensing | Funding rounds and grants (NIH RePORTER + SEC EDGAR) |
| 2025-02-18 | Patent granted | Granted US patents (PatentsView / USPTO) |
Showing 5 of 72 events.
Biomarker capability evidence (15)
Shown in this order: tier desc, then gene symbol.
| Gene | Role | Evidence |
|---|---|---|
| NTM | Trial sponsor | Named in trial inclusion criteria |
| NTM | Trial sponsor | Named in trial inclusion criteria |
| ATP12A | Trial sponsor | Named in trial exclusion criteria |
| ATP12A | Trial sponsor | Named in trial exclusion criteria |
| ATP4A | Trial sponsor | Named in trial exclusion criteria |
Showing 5 of 15 evidence rows.
Not on this page
Checked, with nothing recorded for this organization: companies grouped under this page, related companies not grouped here, fda warning letters, fda untitled letters, fda inspection record, fda recalls, fda import refusals, manufacturing and distribution sites, clia clinical laboratory certificates, and biomarkers this organization publishes on.